8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 24, 2020

Quest Diagnostics Incorporated

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or other jurisdiction of incorporation)

001-12215				16-1387862
(Commission File Number)				(I.R.S. Employer Identification No.)
500 Plaza Drive
Secaucus,	NJ			07094
(Address of principal executive offices)				(Zip Code)
		(973)	520-2700
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 Par Value	DGX	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On August 24, 2020, Quest Diagnostics Incorporated (the “Company”) issued a press release announcing that the Company, along with The Quest Diagnostics Foundation, Inc. (“Quest Foundation”), is launching an initiative to reduce health disparities in underserved communities. The Company will dedicate more than $100 million to expand access to testing, partner with those hit hardest by the COVID-19 pandemic and fund Quest Foundation initiatives. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.  

Item 9.01. Financial Statements and Exhibits

d.    Exhibit    

99.1    Press release of Quest Diagnostics Incorporated dated August 24, 2020.

104    The cover page of this current report on Form 8-K formatted in Inline XBRL.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

August 25, 2020

QUEST DIAGNOSTICS INCORPORATED

By:    /s/ William J. O’Shaughnessy, Jr.

William J. O’Shaughnessy, Jr.

Deputy General Counsel and Secretary

EX-99.1

Quest Diagnostics and Quest Diagnostics Foundation Launch Initiative to Reduce Health Disparities in Underserved Communities

Quest to dedicate more than $100 million to expand access to testing, partner to help those hit hardest by COVID-19 and fund Foundation initiatives

SECAUCUS, N.J., Aug. 24, 2020 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, and the Quest Diagnostics Foundation, today announced a wide-ranging initiative to address and reduce health disparities in underserved communities, including those impacted by COVID-19. The multi-year initiative will provide a combination of donated testing services, education programs, partnerships, and financial support.

“Through our role providing testing to the nation, Quest has seen how underserved populations have been disproportionately impacted by COVID-19 with tragic consequences. This major initiative is designed to address health disparities in the communities hardest hit by the pandemic,” said Steve Rusckowski, Chairman, President and CEO of Quest Diagnostics. “This values-based commitment builds on existing work we have done with Federally Qualified Health Centers (FQHCs) and others. Quest plans to donate testing services and fund a range of initiatives estimated to total more than $100 million aimed at improving access to testing and awareness of the value of diagnostic insights, which are the basic building blocks needed to build healthier communities.”

The initiative will focus on serving people of color, elderly and homeless populations in locations throughout the U.S. The company and the Quest Foundation will partner with FQHCs, long term care facilities, schools and universities, community organizations and others to find new ways to address health disparities.

The initiative aims to:

• Close gaps in COVID-19 testing availability

• Address key social determinants of health that, in the past, have limited access to testing and better health in some communities

• Enable long-term impact in communities

• Drive awareness and education on the importance of appropriate diagnostic testing for health and wellness

“Everyone at Quest has been working so hard through the pandemic to serve patients, and all 47,000 of us want to ensure that every patient has access to the diagnostic insights they need to empower better health,” said Mr. Rusckowski. “Quest is fortunate to be able to commit to this initiative at this difficult time to help those most in need.”

More details on this initiative, as well as how to engage with the company and the Foundation, will be available soon on the company’s website. Inquiries on the initiative can be sent to CommunityHealthInitiative@questdiagnostics.com.

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

About COVID-19 Testing by Quest Diagnostics

Quest Diagnostics is at the forefront of response to the COVID-19 pandemic, working to broaden access to laboratory insights to help us all lead healthier lives. We provide both molecular diagnostic and antibody serology tests to aiding the diagnosis of COVID-19 and immune response. Our COVID-19 test services are based on tests that have received or are expected to receive FDA emergency use authorization and which also meet our high standards for quality. We provide data on COVID-19 testing to various federal and state public health authorities, including the Centers for Disease Control and Prevention, and participate in studies with government and private institutions, aiding COVID-19 public health response and research. Through our team of dedicated phlebotomists, couriers, air fleet team, and laboratory professionals, Quest Diagnostics won't stop until quality testing is broadly available to patients and communities across the United States. 

For more information about the latest developments with our COVID-19 testing, visit: newsroom.questdiagnostics.com/COVIDTestingUpdates.

About The Quest Diagnostics Foundation

The Quest Diagnostics Foundation was established in 2001. Its purposes include promoting the benefits of healthcare and wellness and the prevention, early detection, monitoring and treatment of disease, and educating the general public and healthcare professionals regarding healthcare issues.

SOURCE Quest Diagnostics

For further information: Denny Moynihan, Quest Diagnostics (Media): 973-520-2800, or Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900

XML

Cover	Aug. 24, 2020
Cover [Abstract]
Document Type	8-K
Document Period End Date	Aug. 24, 2020
Entity Registrant Name	Quest Diagnostics Inc
Entity Incorporation, State or Country Code	DE
Entity File Number	001-12215
Entity Tax Identification Number	16-1387862
Entity Address, Address Line One	500 Plaza Drive
Entity Address, City or Town	Secaucus,
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07094
City Area Code	(973)
Local Phone Number	520-2700
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 Par Value
Trading Symbol	DGX
Security Exchange Name	NYSE
Entity Emerging Growth Company	false
Entity Central Index Key	0001022079
Amendment Flag	false